PCOS Is Now PMOS: What the New Name Means for Diagnosis, Treatment, and Your Health

Introduction

After more than a decade of global advocacy, polycystic ovary syndrome is getting a new name. At the European Congress of Endocrinology in Prague, an international coalition of 56 academic, clinical, and patient organizations announced that PCOS will now be known as polyendocrine metabolic ovarian syndrome, or PMOS. The consensus, published in The Lancet, marks the culmination of a 14-year effort to correct a long-standing problem: the original name was misleading and contributed to delayed diagnoses, fragmented care, and stigma. For the millions of women living with this condition — which affects roughly one in eight females worldwide, according to a 2024 study in JAMA Internal Medicine — the new name promises to reshape how the disease is diagnosed, treated, and researched.

Background: Why the Name PCOS Was Always a Problem

Polycystic ovary syndrome has long been recognized as a poorly named condition. The term “polycystic” refers to the appearance of multiple small follicles on the ovaries, but not everyone with the condition has them. In fact, many women with PCOS have completely normal-looking ovaries on ultrasound. That single discrepancy has caused endless confusion. Women were often told they didn’t have PCOS because no cysts were visible, even when they presented with classic symptoms like irregular periods, excess facial hair, acne, weight gain, and fertility challenges. This misalignment between the name and the clinical reality has led to a cascade of negative consequences: missed early interventions for metabolic and cardiovascular risks, patients shuffled between gynecologists and endocrinologists with no integrated care, and a persistent stigma that made some women feel their condition was merely a reproductive issue rather than a whole-body disorder.

The old name also skewed research priorities. Funding and studies often focused narrowly on ovarian morphology and fertility, rather than on the underlying drivers of the disease: insulin resistance, androgen excess, and chronic low-grade inflammation. Yet the metabolic consequences of PCOS are profound. Women with the condition face up to four times the risk of developing type 2 diabetes, and they are at significantly higher risk for cardiovascular disease, including hypertension and dyslipidemia. Renaming the condition was never just about semantics — it was about aligning the medical label with the biological reality and ensuring that every clinician, from primary care to cardiology, recognizes the condition for what it truly is.

The Evidence: How the Consensus Was Reached

The name change is not an overnight editorial decision. It is the product of a structured, 14-year international process involving 56 organizations from the worlds of endocrinology, gynecology, metabolic medicine, and patient advocacy. According to the consensus statement published in The Lancet, the goal was to prioritize a medically accurate name that explicitly acknowledges the condition’s multisystem nature, rather than simply retaining the familiar PCOS acronym. The preferred terms that emerged were “ovarian,” “metabolic,” and “polyendocrine,” which together capture the core features of the disorder. The final choice — polyendocrine metabolic ovarian syndrome — places endocrine and metabolic dysfunction at the forefront while still acknowledging that ovarian dysfunction is part of the picture, without letting it dominate.

The announcement was delivered at the European Congress of Endocrinology in Prague and published in The Lancet on May 12, 2026. Because this is a consensus statement rather than a new clinical trial, traditional research metrics like sample size, confidence intervals, or hazard ratios are not applicable. Instead, the evidence base comes from decades of existing research that demonstrated the inadequacies of the PCOS name. For context, a landmark 2024 study published in JAMA Internal Medicine estimated the global prevalence of PCOS at roughly 1 in 8 women, underscoring the scale of the population affected by diagnostic confusion and fragmented care. The authors of the consensus statement argue that removing “cyst” from the name eliminates the single biggest source of misdiagnosis, while adding “endocrine” and “metabolic” explicitly signals to clinicians that this is a whole-body condition requiring comprehensive evaluation — not just an ultrasound.

The lead authors and the full list of participating organizations were not detailed in the initial announcement, though the consensus was reached under the auspices of major endocrine societies and patient groups. The statement emphasizes that the new name should help redirect research funding toward the metabolic and hormonal root causes, such as insulin resistance, androgen excess, and chronic inflammation, rather than the presence or absence of ovarian cysts.

What This Means for You

If you have been diagnosed with PCOS — or suspect you might have it — the shift to PMOS could have a tangible impact on your healthcare journey. First, it may shorten the time to diagnosis. Too many women have been dismissed by clinicians who looked for ovarian cysts and found none, only to realize years later that they had the condition all along. With “polycystic” removed from the name, the diagnostic criteria can be more accurately focused on the hormonal and metabolic markers that truly define the syndrome: irregular ovulation, clinical or biochemical signs of high androgens, and the exclusion of other disorders. This means you won’t need to “prove” you have cysts to get the right diagnosis.

Second, the new name reinforces that managing PMOS requires more than a trip to the gynecologist. Because “endocrine” and “metabolic” are now in the label, your care team is more likely to include endocrinologists, dietitians, cardiologists, and mental health professionals. This integrated approach can catch insulin resistance, prediabetes, and cardiovascular risks earlier, giving you a better chance to prevent long-term complications. If you are already living with a PCOS diagnosis, you don’t need to do anything differently right away — the medical understanding of the condition hasn’t changed, just the name. But over time, expect your doctors to start using PMOS, and feel empowered to ask for the full spectrum of metabolic and endocrine screenings you deserve.

Expert Perspective

Sherry Ross, MD, a board-certified OB-GYN and women’s health expert at Providence Saint John’s Health Center in Santa Monica, told Healthline that “PCOS has long been a confusing and misleading diagnosis for women.” She explained that the new name, PMOS, “gives a more accurate and inclusive name to this medical condition, which affects women far beyond the ovaries.” Steven Vasilev, MD, a gynecologic oncologist and founder of the Lotus Endometriosis Institute, added that “by putting ‘endocrine’ and ‘metabolic’ in the name, PMOS tells clinicians this is a whole-body condition, not just a gynecologic diagnosis.” Both experts acknowledged that the transition will take time, as the old acronym is deeply embedded in medical literature and patient communities. However, Ross emphasized that “it is worth the time and patience to better diagnose this whole-body medical phenomenon.” It is worth noting that a name change alone will not automatically solve all diagnostic and care gaps; widespread education of clinicians, updated guidelines, and patient awareness campaigns will be essential to translate the new label into meaningful health improvements. Future research should also evaluate whether the rename leads to measurable changes in time to diagnosis, metabolic screening rates, or long-term outcomes.

Frequently Asked Questions

Q: What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome. It is the new official name for the condition formerly known as polycystic ovary syndrome (PCOS).

Q: Why was PCOS renamed to PMOS?

The name was changed because “polycystic ovary syndrome” was misleading. Many affected women do not have ovarian cysts, leading to missed diagnoses and delayed care. The new name emphasizes that the condition is a multisystem endocrine and metabolic disorder, not just a gynecological problem.

Q: Do I still have the condition if I don’t have ovarian cysts?

Yes. Under the old name, the absence of cysts on ultrasound often led clinicians to rule out PCOS incorrectly. The new PMOS name removes this requirement. Diagnosis is based on a combination of clinical and biochemical signs such as irregular ovulation, elevated androgen levels, and exclusion of other disorders, with or without visible cysts.

Q: How will the name change affect my treatment?

Your treatment plan itself may not change immediately, but the name change is designed to encourage a more holistic approach. It signals to all healthcare providers that PMOS involves metabolic and cardiovascular risks that need to be monitored, alongside reproductive concerns. Over time, you may find more coordinated care across gynecology, endocrinology, and cardiology.

Q: When will doctors start using PMOS instead of PCOS?

The transition will be gradual. Medical societies will need to update clinical guidelines, and it will take time for the term PMOS to appear in medical records, patient materials, and research. Experts expect it may take several years before PMOS becomes the standard term in everyday practice.

Sources

• Expert consensus panel. (2026). Renaming polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
• Liu et al. (2024). Prevalence of polycystic ovary syndrome among women of reproductive age. JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2848540